Expert Interview
Exploring the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy for obesity and type 2 diabetes
Ticker(s): GUTS, NVO, LLYInstitution: Mayo Clinic
- Endocrinologist and part of the Mayo Clinic Precision Medicine for Obesity program
- Treats over 1000 patients for obesity per year
- Clinical and research focus on understanding obesity's pathophysiology to develop more effective therapeutic interventions, especially for perimenopausal women and breast cancer survivors.
Roughly how many patients with obesity/T2D do you manage?
Added By: ben_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for Rejuva?
Added By: ben_adminWhat is your high level view on the potential of gene therapies for weight management?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
